References

Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)

2025 · External reference

Clearing the hurdles for CAR-T cell treatment

10.1038/s41577-025-01228-4 · 2025 · External reference

Patient access to gene therapy medicinal products: a comprehensive review

10.1136/bmjinnov-2020-000425 · 2021 · External reference

Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation

10.1016/j.jtct.2025.05.012 · 2025 · External reference

Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries

10.1182/blood.2025030872 · 2026 · External reference

Access to CAR T-cell therapy across diverse global markets

10.1182/blood.2025032585 · 2026 · External reference

Availability and financing of CAR-T cell therapies: A cross-country comparative analysis

10.1016/j.healthpol.2024.105153 · 2024 · External reference

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

10.1186/s12913-023-09494-5 · 2023 · External reference

Improving Chimeric Antigen Receptor T Access in Latin America: Promises, Barriers, and a Call to Action

10.1200/go-25-00760 · 2026 · External reference

CAR-T in resource-limited regions

2026 · External reference

COVID-19 Vaccine Acceptance and Beliefs among Black and Hispanic Americans

10.1371/journal.pone.0256122 · 2021 · External reference

Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma

10.1016/j.bict.2025.100007 · 2025 · External reference

Prevailing Public Perceptions of the Ethics of Gene Therapy

10.1089/hum.2014.030 · 2014 · External reference

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

10.1016/s2352-3026(22)00226-5 · 2022 · External reference

The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies

10.1007/s40290-023-00480-0 · 2023 · External reference

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments

10.1007/s11899-021-00635-3 · 2021 · External reference

Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review

10.1007/s41669-025-00614-x · 2026 · External reference

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020

10.1001/jamainternmed.2022.4924 · 2022 · External reference

High drug prices are not justified by industry’s spending on research and development

10.1136/bmj-2022-071710 · 2023 · External reference

Pharmaceutical drug development: high drug prices and the hidden role of public funding

10.1007/s42977-020-00025-5 · 2021 · External reference

Santander Global Summit in Transplantation: Supporting Global Convergence in the Shared Goals of Sufficiency, Transparency, and Oversight

10.1097/tp.0000000000005222 · 2025 · External reference

Promoting Equitable and Affordable Patient Access to Safe and Effective Innovations in Donation and Transplantation of Substances of Human Origin and Derived Therapies

10.1097/tp.0000000000005169 · 2025 · External reference

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

10.1016/s1474-4422(23)00194-1 · 2023 · External reference

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

10.1038/s41571-023-00832-4 · 2024 · External reference

CAR T-cell therapy in autoimmune diseases

10.1016/s0140-6736(23)01126-1 · 2023 · External reference

Stem cell therapies for diabetes

10.1038/s41591-025-03767-8 · 2025 · External reference

Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies

10.1038/s41392-025-02313-9 · 2025 · External reference

From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives

10.3390/cells10112845 · 2021 · External reference

On CAR-Ts, decentralized in-house models, and the hospital exception. Routes for sustainable access to innovative therapies

10.1093/jlb/lsac027 · 2022 · External reference

Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility

10.1186/s12967-025-06400-x · 2025 · External reference

Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases

10.1016/j.ymthe.2025.09.049 · 2025 · External reference

Balancing Safety and Innovation for Cell-Based Regenerative Medicine

10.1056/nejmsr1715626 · 2018 · External reference

Stem/progenitor cell-based therapy for Duchenne muscular dystrophy

10.3389/fcell.2025.1640275 · 2025 · External reference

Unresolved reference

External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

2023 · External reference

Beyond human limits: the ethical, social, and regulatory implications of human enhancement

10.3389/fmed.2025.1595213 · 2025 · External reference

Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt

2021 · External reference

Enabling manufacture and access to advanced therapy medicinal products in low- and middle-income countries

10.1016/j.hlife.2025.07.001 · 2025 · External reference

CAR-T and cellular gene therapies are too expensive

10.1038/s41591-024-03231-z · 2024 · External reference

CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India

10.1016/s2352-3026(25)00040-7 · 2025 · External reference

A Discount on the Cost of Cancer: India’s Homegrown CAR-T Cell Therapy

2024 · External reference

Unresolved reference

2025 · External reference

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article

10.1038/s41409-026-03044-3 · 2026 · External reference

10.3389/frhem.2026.1891877 · 2026 · Admitted local publication

Addressing Risks Derived From the Commodification of Substances of Human Origin: A European Proposal Applicable Worldwide

10.1097/tp.0000000000004527 · 2023 · External reference

Rethinking CAR-T manufacturing paradigms: terminology, operational considerations, and economic trade-offs

10.1016/j.jcyt.2026.102884 · 2026 · External reference

Manufacturing Characteristics and Early Outcomes of a Tandem aCD22-aCD19 CAR-T Therapy for Childhood and Adult Relapsed/Refractory Acute Precursor B Lymphoblastic Leukemia

10.1016/j.jtct.2025.01.020 · 2025 · External reference

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL

10.1158/2643-3230.bcd-26-0115 · 2026 · External reference

Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities

10.1016/j.jcyt.2017.07.005 · 2017 · External reference

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework

10.1016/j.jcyt.2026.102939 · 2026 · External reference

An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent β-thalassemia

10.1182/bloodadvances.2025016053 · 2025 · External reference